Candesartan in the treatment of hypertension and heart failure
Authors:
J. Vítovec; J. Špinar
Published in:
Kardiol Rev Int Med 2012, 14(4): 258-261
Category:
Overview
Candesartan is a modern AT1 receptor blocker for angiotensin II – sartans. It has favourable pharmacokinetic as well as pharmacodynamic properties. It has shown efficacy in terms of a reduction in morbidity and mortality resulting from such diseases in many clinical trials with respect to both hypertension and heart failure. A brief overview of the pharmacological effects and results of clinical trials (SCOPE, TROPHY, RESOLVED and CHARM) is presented.
Keywords:
candesartan – hypertension – heart failure
Sources
1. Vítovec J, Špinar J. Farmakoterapie kardiovaskulárních onemocnění. 2. vyd. Praha: Grada 2004: 248.
2. Slíva J. Candesartan v léčbě kardiovaskulárních onemocnění. Farmakoterapie 2012; 8: 118–122.
3. Trial Results Center. Table summary of clinical trials for candesartan. Available from: www.trialresultscenter.org/DR5-candesartan%20clinical%20trials.htm.
4. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.
5. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685–1697.
6. McKelvie RS, Yusuf S, Pericak D et al. Comparison of candesartan, enalapril and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056–1064.
7. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.
8. McMurray JJ, Östergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–771.
9. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to angiotensin-converting-enzyme inhibitors: the CHARM--Alternative trial. Lancet 2003; 362: 772–776.
10. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362: 777–781.
11. SÚKL ČR. Příbalová studie Candesartanu. Dostupné na: www.sukl.cz/download/pil/PI25209.pdf.
12. Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag 2011; 7: 749–759.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2012 Issue 4
Most read in this issue
- Cardiorenal syndrome – from a nephrologist’s point of view
- Affect statin myopathy reduced form of coenzyme Q10?
- Cardiorenal syndrome with chronic heart failure – from a cardiologist‘s point of view
- Acute kidney failure and cardiovascular complication